Psychedelic Pharmacotherapy for Gambling Disorder: Evidence and Gaps

Opioid Antagonists Lead Pharmacological Treatment for Gambling Disorder

Opioid antagonists such as naltrexone and nalmefene currently have the strongest evidence base among pharmacological treatments for gambling disorder (GD), according to a narrative review published in October 2026 (OpenAlex W7225095906). These agents have demonstrated statistically significant reductions in GD symptoms compared to placebo, especially in individuals with high levels of gambling craving. No medication is currently approved by major regulators such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for GD, but opioid antagonists are considered a first-line off-label adjunct to cognitive-behavioral therapy (CBT) in clinical guidelines.

The review synthesizes data from systematic reviews, network meta-analyses, and clinical trials. Other drug classes—including antidepressants, antipsychotics (e.g., olanzapine), and anticonvulsants (e.g., topiramate)—have generally failed to outperform placebo in most studies. Mood stabilizers may help in cases of comorbid bipolar disorder, but the evidence remains limited and inconclusive.

Psychedelics: Experimental Status and Mechanistic Rationale

Psychedelics such as psilocybin and ketamine are identified as experimental agents for GD, with insufficient clinical data to support their use at this time. The review notes that these compounds have not yet moved beyond early-phase, small-scale studies or open-label case series in the context of behavioral addictions.

The mechanistic rationale for considering psychedelics in GD stems from their effects on neuroplasticity, reward circuitry, and cognitive flexibility—domains implicated in both substance use and behavioral addictions. For example, psilocybin is known to modulate serotonin 2A receptors, potentially disrupting maladaptive patterns of thought and behavior. Ketamine, an NMDA receptor antagonist, has shown rapid-acting antidepressant effects and may transiently alter reward processing. However, unlike opioid antagonists, psychedelics have not yet demonstrated efficacy in randomized controlled trials (RCTs) for GD.

Research Gaps and Policy Implications

The absence of robust clinical data on psychedelics for GD highlights a significant research gap. The review calls for larger, well-controlled trials and the development of biomarkers to personalize treatment approaches. Regulatory agencies such as the FDA and EMA have not issued guidance or initiated regulatory pathways for psychedelic use in GD as of late 2026.

This gap also signals an opportunity for academic and industry sponsors to design rigorous trials that address both efficacy and safety endpoints. Notably, the review underscores that most existing studies on psychedelics in behavioral addictions are underpowered and lack appropriate controls, limiting generalizability. The identification of patient subgroups—such as those with high impulsivity or treatment-resistant GD—could help target future research and optimize trial design.

• Non-obvious insight: The review points out that the neurobiological overlap between GD and substance use disorders may not translate directly to treatment efficacy, as evidenced by the limited success of agents effective in substance use disorders when applied to GD. This suggests that mechanistic similarity does not guarantee clinical utility, a critical consideration for psychedelic trial design.

Risks, Unknowns, and Ethical Considerations

Psychedelics remain unproven for GD, and their use outside of approved research protocols carries legal, ethical, and clinical risks. Adverse effects—including acute psychological distress, perceptual disturbances, and the potential for misuse—must be carefully monitored in any future trials. The review also notes methodological limitations in the current evidence base, such as small sample sizes, open-label designs, and short follow-up periods.

There is also a risk that premature clinical adoption or off-label use of psychedelics for GD could outpace the evidence, potentially exposing vulnerable patients to harm. Regulatory and ethical oversight will be essential as the field moves forward.

Looking Ahead: Next Steps for Research and Practice

Future progress in psychedelic pharmacotherapy for GD will depend on the successful design and execution of large, controlled clinical trials, ideally with biomarker-driven patient stratification. Collaboration between academic centers, industry sponsors, and regulatory bodies will be crucial to ensure trials are adequately powered and methodologically sound. Until such data are available, opioid antagonists remain the best-supported pharmacological adjunct to CBT for GD, while psychedelics should be considered investigational and used only within approved research protocols.

By Dr. Alex Morgan, PhD (Neuroscience). Reviewed by Dr. Priya Shah, MD, on 2026-11-03. Research based on primary literature and regulatory sources.